Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Documenti analoghi

• The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
  di: van Kempen, Zoé LE, et al.
  Pubblicazione: (2017)
• Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
  di: Leurs, Cyra E, et al.
  Pubblicazione: (2017)
• Infusion-related events during natalizumab: No need for post-infusion monitoring
  di: Loonstra, Floor C, et al.
  Pubblicazione: (2019)
• Disease activity following pregnancy-related discontinuation of natalizumab in MS
  di: Kleerekooper, Iris, et al.
  Pubblicazione: (2017)
• SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort
  di: van Kempen, Zoé L. E., et al.
  Pubblicazione: (2021)